🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

392 results for “CIS” Clear

  1. NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

    Chongqing Precision Biotech Co., Ltd

    Bone Sarcoma

    phase 1 mab active

    1 trial

  2. OKN4395

    Chongqing Precision Biotech Co., Ltd

    Solid Tumours

    phase 1 small molecule active

    1 trial

  3. PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

  4. PBCAR19B

    Chongqing Precision Biotech Co., Ltd

    CD19 Expressing Malignancies

    phase 1 gene therapy completed

    1 trial

  5. PBCAR269A

    Chongqing Precision Biotech Co., Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 gene therapy terminated

    1 trial

  6. PBGENE-HBV

    Chongqing Precision Biotech Co., Ltd

    HEPATITIS B CHRONIC

    phase 1 mab active

    1 trial

  7. PIC1 Injection

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  8. PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Healthy

    phase 1 small molecule active

    1 trial

  9. PRX-P4-003, (-)-FCF

    Praxis Precision Medicines

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. PTOC1

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  11. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  12. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  13. Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  14. Pneumococcal Vaccine, Polyvalent (23-valent)

    Praxis Precision Medicines

    HIV Infections

    phase 1 mab completed

    1 trial

  15. RUC-4 Compound

    Chongqing Precision Biotech Co., Ltd

    Coronary Disease

    phase 1 small molecule completed

    1 trial

  16. TAEST16001

    Chongqing Precision Biotech Co., Ltd

    Liver Cancer Stage IV

    phase 1 small molecule completed

    1 trial

  17. TAEST16001 cells

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  18. Targeted CEA CAR-T

    Chongqing Precision Biotech Co., Ltd

    Advanced Lung Cancer

    phase 1 mab active

    4 trials

  19. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  20. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  21. [11C]CPPC Injection

    Chongqing Precision Biotech Co., Ltd

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule terminated

    1 trial

  22. anti-BCMA/CD70-CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    CAR T Cell Therapy

    phase 1 mab active

    1 trial

  23. anti-CD19 CAR NK

    Chongqing Precision Biotech Co., Ltd

    NHL

    phase 1 mab active

    1 trial

  24. anti-CD19-CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources